DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition
|
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Personnel English Version Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation QIAGEN announces CEO leadership transition Venlo, The Netherlands, October 7, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Peer M. Schatz, Chief Executive Officer, has notified the Company that he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Advisor to the Supervisory Board and transition into this role in the coming weeks. The Supervisory Board will now start a search for a permanent CEO. In the meantime, Thierry Bernard, Senior Vice President, Head of Molecular Diagnostics Business Area, will now act as interim CEO and work in tandem with Roland Sackers, Chief Financial Officer. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands ISIN: NL0012169213 Frankfurt Stock Exchange, regulated market (Prime Standard) Contact John Gilardi Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 and +1 240 686 2222
07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | QIAGEN N.V. |
| Hulsterweg 82 | |
| 5912 PL Venlo | |
| Netherlands | |
| Phone: | +31 7735566 - 00 |
| Fax: | +31 77 35566-58 |
| E-mail: | [email protected] |
| Internet: | www.qiagen.com |
| ISIN: | NL0012169213 |
| WKN: | A2DKCH |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
| EQS News ID: | 886527 |
| End of Announcement | DGAP News Service |
|
|
886527 07-Oct-2019 CET/CEST
QIAGEN NV Aktie
Mehrere Buy-Einschätzungen für QIAGEN NV ohne eine einzige Sell-Einschätzung.
Ein positives, wenn auch bescheidenes, Potenzial für QIAGEN NV mit einem Kursziel von 47 € im Vergleich zum aktuellen Kurs von 40.47 €.
